IRLAB Therapeutics Logo

IRLAB Therapeutics

Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.

IRLAB | ST

Overview

Corporate Details

ISIN(s):
SE0012675361 (+1 more)
LEI:
549300JAT34LHEI0DH60
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IRLAB Therapeutics is a drug discovery and development company specializing in novel treatments for neurodegenerative conditions, with a primary focus on Parkinson's disease and other Central Nervous System (CNS) disorders. The company's pipeline is generated by its proprietary research platform, the Integrative Screening Process (ISP), a systems pharmacology discovery method built on an extensive, unique database of CNS compounds. Key clinical-phase candidates include mesdopetam (IRL790), developed to treat levodopa-induced dyskinesia (LIDs), and pirepemat (IRL752), aimed at addressing impaired balance and falls associated with Parkinson's disease.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-20 16:40
Regulatory News Service
Valberedningen utsedd inför IRLAB:s årsstämma 2026
Swedish 41.3 KB
2025-11-20 16:40
Regulatory News Service
Nomination committee appointed for IRLAB’s annual general meeting 2026
English 40.5 KB
2025-10-29 07:00
Quarterly Report
Swedish 577.5 KB
2025-10-29 07:00
Quarterly Report
English 571.8 KB
2025-10-09 17:15
Board/Management Information
IRLAB utser Gustaf Albèrt till ny Chief Financial Officer
Swedish 39.5 KB
2025-10-09 17:15
Board/Management Information
IRLAB appoints Gustaf Albèrt as the new Chief Financial Officer.
English 39.5 KB
2025-08-29 07:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i IRLAB Therapeutics AB
Swedish 47.7 KB
2025-08-29 07:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in IRLAB Therapeutics AB
English 47.0 KB
2025-08-27 07:00
Interim Report
Swedish 377.6 KB
2025-08-27 07:00
Interim Report
English 373.0 KB
2025-08-21 11:00
Board/Management Information
IRLAB appoints Roy Jonebrant as interim CFO
English 38.2 KB
2025-08-21 11:00
Board/Management Information
IRLAB utser Roy Jonebrant till tillförordnad CFO
Swedish 38.8 KB
2025-08-11 09:00
Board/Management Information
IRLAB's CFO Viktor Siewertz leaves the company for a new leading position
English 39.6 KB
2025-08-11 09:00
Board/Management Information
IRLAB:s CFO Viktor Siewertz lämnar bolaget för ny ledande position
Swedish 40.0 KB
2025-07-18 18:31
Share Issue/Capital Change
IRLAB announces the outcome of the company’s rights issue
English 64.4 KB

Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IRLAB Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-05 Kristina Torfgård Other Buy 9,000 140,850.00 SEK
2024-08-05 Kristina Torfgård Other Buy 4,500 70,875.00 SEK
2024-05-14 Gunnar Olof Olsson Other Buy 2,000 31,000.00 SEK
2024-05-10 Daniel Johnsson Other Buy 20,000 259,680.00 SEK
2023-04-03 Joakim Tedroff Other Buy 51,430 2,038,685.20 SEK
2022-09-01 Richard Godfrey Other Buy 5,000 174,457.00 SEK
2022-08-30 Viktor Siewertz Other Buy 40 1,420.00 SEK
2022-08-29 Viktor Siewertz Other Sell 40 1,408.00 SEK
2022-07-15 Joakim Tedroff Other Other 84,148 N/A
2022-05-31 Viktor Siewertz Other Buy 4,500 170,370.00 SEK

Peer Companies

Personalis, Inc. Logo
Cancer genomics & liquid biopsy for early recurrence detection & guiding precision therapies.
United States of America
PSNL
Perspective Therapeutics, Inc. Logo
Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.
United States of America
CATX
PharmAbcine Inc. Logo
Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.
South Korea
208340
Pharma Foods International Co., Ltd. Logo
Researches and sells functional ingredients and direct-to-consumer health & beauty products.
Japan
2929
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain
PHM
Pharmanutra Logo
Researches and markets nutritional supplements & medical devices for all ages.
Italy
PHN
PHARMARESEARCH BIO Co., Ltd. Logo
A global biopharma firm creating regenerative medicine, pharmaceuticals, devices, and cosmetics.
South Korea
217950
PharmaResearch Co., Ltd. Logo
Develops regenerative medicine, devices & cosmetics using marine biotechnology.
South Korea
214450
PharmaSGP Holding SE Logo
Develops and markets leading natural OTC drugs for chronic conditions in the European market.
Germany
PSG
Pharmena S.A. Logo
Develops dietary supplements using its patented 1-MNA molecule to support healthy aging.
Poland
PHR

Talk to a Data Expert

Have a question? We'll get back to you promptly.